Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note published on Monday morning. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners lowered their price target on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Trading Down 6.2 %

Shares of NASDAQ:AWH opened at $0.85 on Monday. The firm has a 50 day moving average of $0.92 and a 200-day moving average of $1.76. Aspira Women’s Health has a 12 month low of $0.74 and a 12 month high of $6.01. The stock has a market capitalization of $13.69 million, a PE ratio of -0.59 and a beta of 1.47.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. On average, research analysts predict that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.